Share Name Share Symbol Market Type Share ISIN Share Description
Eco Animal Health Group Plc LSE:EAH London Ordinary Share GB0032036807 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  2.00 0.57% 350.00 7,353 08:08:07
Bid Price Offer Price High Price Low Price Open Price
340.00 360.00 350.00 348.00 348.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 72.11 5.21 3.82 91.6 236
Last Trade Time Trade Type Trade Size Trade Price Currency
12:43:04 O 4,306 355.2959 GBX

Eco Animal Health (EAH) Latest News

More Eco Animal Health News
Eco Animal Health Investors    Eco Animal Health Takeover Rumours

Eco Animal Health (EAH) Discussions and Chat

Eco Animal Health Forums and Chat

Date Time Title Posts
23/6/202112:41Eco Animal Health Group: Early dewormer gets OK1,254

Add a New Thread

Eco Animal Health (EAH) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Eco Animal Health trades in real-time

Eco Animal Health (EAH) Top Chat Posts

Eco Animal Health Daily Update: Eco Animal Health Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker EAH. The last closing price for Eco Animal Health was 348p.
Eco Animal Health Group Plc has a 4 week average price of 322p and a 12 week average price of 317.50p.
The 1 year high share price is 397.50p while the 1 year low share price is currently 201.50p.
There are currently 67,517,126 shares in issue and the average daily traded volume is 59,668 shares. The market capitalisation of Eco Animal Health Group Plc is £236,309,941.
cerrito: Interested to read that ANP today reported very strong sales growth YTD in China..though that is for reasons that do not apply to EAH-namely ban on antibiotic growth promoters in animal feed.
cerrito: Article in the FT today about the big fall in wholesale pork prices in China currently at their lowest since 2019 and half of recent peaks. Also the futures market for wholesale pork has fallen 30pc since it started in January. There seems to be big oversupply. In theory this should mean that EAH has had a strong recent run in China that may be slowing down. We should hear soon.
aimingupward2: It’s interesting to look at the share price chart over the past 5 yrs - a fall from around 650p to support last year at 200p and the start of a climb back over the last few months. It suggests, decent trading permitting, that there is still quite a way to go yet.
1aconic: Yup, everytime there's news about it there's a dip. What's stunning though is how EAH maintained revenue through market share. I can't really think of a covid comparison... I'm sure there must be a good one (which if anyone points out I'll no doubt wish I'd bought as heavily as EAH!!)...
cerrito: No idea if EAH involved in this hxxps://;utm_medium=Email&utm_content=NL-African+Swine+Fever+Update&utm_campaign=NL-African+Swine+Fever+Update_20210516_0600&oly_enc_id=8786C7274956B8R
igoe104: I see the naked trader is looking to buy these, that's two shares in two weeks that I hold he's written about. Another I was waiting to buy after the online seminar was Eco Animal Healthcare (EAH). I tend to hesitate to buy shares on a high rating like this one as any disappointment can lead to a big drop. But the animal healthcare market is just getting bigger and bigger- this one makes and develops animal healthcare products across the globe. According to management it is trading well above expectations and the real excitement coming from China. It is doing especially well there with massive demand for its flagship product. So even given its high rating there could be a lot more to come and results in June I suspect will be really good. Brokers on research-tree reckon it is the top pick in the vet pharma space on both valuation and growth considerations. (If you want a 20c discount on the broker notes go to set up free account and click upgrade then put nakedtrader into the promo code).
igoe104: Alittle bit of ASF should benefit EAH, because Chinese farmers are going to be worried into buying more quality vaccines rather than the cheaper Chinese alternatives. As long as it doesn't spread across the country, which it hasn't so far this year EAH should benefit.
cerrito: I am finding it difficult to get a handle on how important the ASF outbreak is for EAH. The Rabobank report is only available for their clients. The FT had a good story and reports that future hog prices on the Dalian exchange have gone up which would make one think that producers will give their piglets more TLC. I see that ANP have made the same comment as EAH - namely that the emergence of bigger more modern farms in China makes it easier to do business.
ifaze: hope you increased your holding Cerito before the latest news came out. Not surprising that div was cut when China, their biggest market, lost over half the pig population because of Swine flu. figures of culling 100s of millions of pigs is quite frightening. Confident that div will be re introduced soon and I suspect there is plenty more upside to the share price. I will be top slicing on any rises because I hold far too many shares.
cerrito: I have been going through both the recently published AR and the interims to see if I should increase my holding. I think I will stay where I am for now but would appreciate comments from you all as to where I have misunderstood. One big reason for me not buying more is I am having difficulty in understanding the company and one reason for that is that they do not appear to bother with IR for their retail investors. I take the point that it appears unlikely that they will need to do a fund raise in the immediate future and that those holding over 3% have a combined 65% share holding-ie retail investors are less important than in some other companies. That said they could have been more welcoming in their AGM like for example CWR and ITM or at the very least have done an Investor Meets Company type operation. I should add that the Finances seem better managed than in the past. It was surprising to read n page 126 of the AR that over an extended period an ex Director had helped herself to £300k+ without it being picked by internal or external auditors. Also, a bit disorientating to see that in the two years to March 2020 they paid out £18m in dividends and then we read in the latest interims they had to cut back on their R&D programme as they had insufficient cash. Suggests that perhaps a,lack, in the past, of long term strategic financial planning. What is welcome that there is now more transparency as to where the cash is i.e., China or non China than we seem to have had in the past. It is of course great that consolidated net cash grew from £9.8m at end March 2020 to £12.9m at end September 2020. However, that was due to cash balances of the Chinese company growing from £5.3m to £9.7m and cash balances ex China decreasing from £4.5m to £3.2m. The interims recognize that this cash balance in China-51% owned by EAH- gets transferred by dividends, as one would expect. It would be interesting to know when the next dividend will be paid. My reading of Pages 105/7 of the AR is that EAH would have got £1.6m and £0.97m in FY 2018/19 and 19/20 respectively…but please check that. Let’s hope that this next dividend is going to be higher. My reading of page 106 of the AR which shows a decline in 2020 over 2019 in plant and equipment of the Chinese JV is that the new factory in China is not owned by the JV but rather one assumes by a 100% owned EAH company…is that how you understand it? Begs the question to me is how they realize their factory investment in pounds sterling. All in all, I can well understand why they are not paying a dividend and I go on the basis that any dividend for this FY will be token. I note that the overdraft facility reported on Page 115 of the AR was new. I admit I am surprised that this facility repayable on demand is secured with what would appear to be a highish margin of 1.8%. All seems rather odd to me and suggests that the bank not all that comfortable. Page 116 tells us that the weighted average incremental borrowing rate for lease finance is a, to me, high 7.1%, I was interested to read page 87 of the AR with its good table of in which geographic markets they make their Ebitda. Interesting to see that in the year to 3/20 S and SE Asia far more profitable than China and Japan as regards adjusted ebitda to revenue from external customers and total assets but guess the picture will be different this FY
Eco Animal Health share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Eco Animal..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210625 13:42:24